Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin Use Post published:February 24, 2026 Post category:Psychedelic Bulletin/Pα+
The Psychedelic News Feed: February 16 – 22, 2026 Post published:February 23, 2026 Post category:Psychedelic News Feed Archive
After the Readout: How the Field Is Interpreting Compassā Phase 3 Psilocybin Data Post published:February 20, 2026 Post category:Analysis/News/Pα+
Q1 2026 Psychedelic Drug Development Pipeline: Bullseye Charts Post published:February 19, 2026 Post category:Analysis
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast Post published:February 17, 2026 Post category:Analysis/News/Pα+
BREAKING: Second Positive Phase 3 for Compassā Psilocybin, Though Modest Magnitude Raises Questions Post published:February 17, 2026 Post category:Analysis/News/Pα+
Q4ā25 Psychedelic Lobbying Update Post published:February 13, 2026 Post category:Analysis/News/Pα+
Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola Post published:February 10, 2026 Post category:Interviews/Pα+
The Psychedelic Practitioner Issue 3: Dosing Post published:February 10, 2026 Post category:News/The Psychedelic Practitioner
Pα+ Psychedelic Bulletin #219: Trump Admin. Vetoed Compass Priority Voucher; Ibogaine in Focus; Definium Sued by Former Vendor; Psychedelics Feature in Epstein Files Post published:February 6, 2026 Post category:Psychedelic Bulletin/Pα+